The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
The LIFT-PD study will enroll 75 Parkinson’s patients experiencing apathy across 16 sites in Germany, Bulgaria, Poland and Spain
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
